In The News
May 29, 2024
Aganitha and CCMB Collaboration
CSIR-CCMB and Aganitha signed a framework agreement to apply Generative AI for therapeutic design and research in multiple disease areas.
June 8, 2023
Winners of Accenture Ventures 2023 Challenge
We are pleased to be the winner of the “Accenture Ventures Tech Next Challenge 2023”, in the Science Tech segment, as featured in Times of India.
Events
February 3, 2024
Machine Learning for Molecular Sciences
Chanukya Nanduru presents select real-world case studies of AI/ML in BioPharma R&D at the ML4MS 2024 Conference. He covers applications spanning disease studies, target identification, de novo therapeutic design, delivery vector design, and synthesis modeling.
February 2-3, 2024
Genomics India conference
Manasvi Sharma and Rammohan Pratapa present a poster on “Deep Science + Deep Tech for BioPharma R&D” at Genomics India Conference in
Shiv Nadar Institution Of Eminence, Delhi NCR.
February 2, 2024
3D cell culture
Krishna Harsha Adusumilli presents on “AI powered analysis of 3D cell cultures & organoids” at the 3D cell culture conference hosted by ICT Mumbai. He illustrates with use cases, the role of AI in organoid construction, model development and validation, drug effectiveness testing and Tox testing.
November 23, 2023
IIT Bombay Biopharma Summit 2023
Learn from Manasvi Sharma and Chanukya Nanduru about ways in which deep tech and AI combined with high throughput datasets, deep biology and chemistry knowledge, quantum mechanics, molecular dynamics, cheminformatics and bioinformatics are enabling researchers to find newer targets, design novel molecules and biomolecules, and improve process R&D.
November 23, 2023
IIT Bombay Biopharma Summit 2023
Prasad Chodavarapu presents at the IIT Bombay Biopharma Summit 2023 on “AI/ML in BioPharma R&D: Beyond the Hype with Real-World Case Studies”. In this session, he talks about (a) Practical applications of next-generation AI/ML in biopharma R&D, (b)Through case studies, he will showcase the use of next-gen foundational models and Generative AI in disease research, design of new therapies, and (c) He also presents how we integrate the in silico work with in vitro studies.